BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:FMC-376 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of FMC-376\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06244771-2485@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:FMC-376: Phase 1/2 readout est. (NCT06244771)
DESCRIPTION:FMC-376\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fmc-376#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06244771
URL:https://assetmemo.bio/drug/fmc-376#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07944092-2485@assetmemo.bio
DTSTAMP:20261121T004545Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:FMC-376: Phase 1/2 readout est. (NCT07944092)
DESCRIPTION:FMC-376\, phase 1/2.\nStudy: Ph 1/2 Study to Evaluate Safety & 
 Tolerability of FMC-242 Alone and in Combination in Adults With Advanced S
 olid Tumors\nEstimated primary completion: January 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/fmc-376#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07944092
URL:https://assetmemo.bio/drug/fmc-376#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
